Crimean-Congo Hemorrhagic Fever

Crimean-Congo hemorrhagic fever virus (CCHFV) is a member of the Bunyaviridae family and Nairovirus genus. The viral genome consists of 3 RNA segments of 12 kb (L), 6.8 kb (M), and 3 kb (S). Crimean-Congo hemorrhagic fever (CCHF) is the most widespread tickborne viral infection worldwide: it has bee...

Full description

Saved in:
Bibliographic Details
Published in:Laboratory medicine 2015-08, Vol.46 (3), p.180-189
Main Authors: Shayan, Sara, Bokaean, Mohammad, Shahrivar, Mona Ranjvar, Chinikar, Sadegh
Format: Article
Language:English
Subjects:
Animals
Fever
Genetic diversity
Genomes
Hemorrhagic Fever Virus, Crimean-Congo - genetics
Hemorrhagic Fever Virus, Crimean-Congo - pathogenicity
Hemorrhagic Fever, Crimean - diagnosis
Hemorrhagic Fever, Crimean - epidemiology
Hemorrhagic Fever, Crimean - therapy
Humans
Infections
Medical personnel
Mutation
Patients
Phylogenetics
Phylogeny
Prevention
Proteins
Vaccines
Viruses
Zoonoses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Crimean-Congo hemorrhagic fever virus (CCHFV) is a member of the Bunyaviridae family and Nairovirus genus. The viral genome consists of 3 RNA segments of 12 kb (L), 6.8 kb (M), and 3 kb (S). Crimean-Congo hemorrhagic fever (CCHF) is the most widespread tickborne viral infection worldwide: it has been reported in many regions of Africa, the Middle East, and Asia. The geographical distribution of CCHFV corresponds most closely with the distribution of members of the tick genera, and Hyalomma ticks are the principal source of human infection. In contrast to human infection, CCHFV infection is asymptomatic in all species. Treatment options for CCHF are limited; immunotherapy and ribavirin are effective in the treatment of CCHF; the efficacy of ribavirin in the treatment of CCHF has not yet been proven. This article reviews the history, epidemiology, clinical symptoms, pathogenesis, diagnosis, and treatment of CCHFV, as well as the development of a vaccine against it.
ISSN:0007-5027
1943-7730
DOI:10.1309/LMN1P2FRZ7BKZSCO